



Resonance Health Ltd

ASX / Media Release

18 December 2014

---

## Newsletter to Customers

We will be sending the attached 1 page newsletter to approximately 2000 customers of Resonance Health before the Christmas break and supply a copy of the newsletter for release to the market.

For further information please contact:

**Resonance Health**

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: [lizad@resonancehealth.com](mailto:lizad@resonancehealth.com)

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: [adrianb@resonancehealth.com](mailto:adrianb@resonancehealth.com)

## HepaFat-Scan® awarded West Australian Innovator of the Year Overall Winner 2014



Photo courtesy of The Scene Team

Resonance Health has been awarded West Australian Innovator of the Year Overall Winner for the HepaFat-Scan image analysis system. The HepaFat-Scan technology was developed in collaboration with The University of Western Australia and uses magnetic resonance imaging (MRI) scanners in a non-invasive manner to measure the concentration of fat in the human liver.

Chief Scientific Officer Prof. Tim St Pierre said “HepaFat-Scan addresses the global growing prevalence of fatty liver disease, as well as an unmet need for non-invasive diagnostic tools to diagnose and monitor liver disease. It reports volumetric fraction of fat in the liver, a measure that can be directly compared to a volumetric biopsy measurement, providing patients and doctors with an accurate, non-invasive diagnostic tool as part of a structured intervention protocol or clinical research trial”.

Compared with the reference standard for clinical assessment of liver fat (histopathological assessment), HepaFat-Scan is a more objective and non-invasive MRI based method with better reproducibility and significantly reduced sampling error.

Clinicians and patients can greatly benefit from an accurate HepaFat-Scan measurement of liver fat, to monitor and manage efficacy of treatment, and to provide prognosis for fatty liver disease and associated multiple hepatic and systemic disorders and many other related diseases.

### A Year in Focus

2014 has been an exciting year for Resonance Health, with 50+ new radiology facilities starting to use FerriScan. To date we have also seen a 33% increase in the number of referring clinicians and a growing international awareness of the company and its potential.

## Season’s Greetings and Happy Holidays

We will be closed from Wednesday 24<sup>th</sup> December 2014 to Friday 2<sup>nd</sup> January 2015. Reopening on Monday 5<sup>th</sup> January 2015.

## HepaFat-Scan

HepaFat-Scan was introduced to the market in mid-2014, but more formally launched in Europe at BASL in September and in USA at AASLD in November. The image analysis system provides a non-invasive measurement of percentage fat in the liver and has FDA, TGA and CE mark clearance.

To date HepaFat-Scan has received considerable interest from trial investigators and clinicians and we are currently investigating all opportunities available to maximise its potential use within hospital and pharmaceutical trial environments.

*Please contact us directly should you be interested in receiving more information or a complementary evaluation of HepaFat-Scan.*

E: [info@resonancehealth.com](mailto:info@resonancehealth.com)

## FerriScan®

FerriScan has continued to grow this year, with new centres opening for the very first time in Algeria, Bulgaria, Israel, Kuwait, Morocco and South Africa with additional centres opening in Australia, the United Kingdom, Italy and the USA.

This makes FerriScan a key foundation to our business and we look forward to continued collaborations with our valued customers in 2015.

### Fibrosis


Up and coming within our pipeline portfolio is a product to measure liver fibrosis using MRI imaging. Collaborating with The University of Western Australia, we are working to make the product available to the clinical community as early as possible. Results so far are promising. Further studies on liver fibrosis are planned in 2015.

Following a 2–3 minute scan, patient image data are transmitted electronically to Resonance Health’s central image analysis facility over a secure network. The HepaFat-Scan™ analysis process is applied to provide the volume % of fat in tissue.



Patient scanned at MRI Centre

MRI images transmitted securely to Resonance Health Analysis Centre



HepaFat-Scan analysis process applied to images received

HepaFat-Scan liver fat concentration report available for secure download within target time of 48 hours

